Hikma Pharmaceuticals Plc
24 September 2026
Hikma appoints Rebecca Hall as Chief Financial Officer
London, 24 September 2026 - Hikma Pharmaceuticals PLC (Hikma) announces the appointment of Rebecca Hall as Chief Financial Officer (CFO) and Executive Director. Rebecca (Becky) will join Hikma in Q1 2027. Hikma will confirm the date of Becky's appointment in due course.
Becky joins Hikma from ViiV Healthcare, the global specialist HIV pharmaceutical company majority owned by GSK, with Shionogi as a shareholder, where she is Senior Vice President and Chief Financial Officer, responsible for finance, supply chain and business development. In 2025, ViiV Healthcare generated revenue of close to £8 billion and delivered 11% growth. Becky brings more than twenty years of experience from ViiV Healthcare and GSK, spanning pharmaceuticals and consumer products. She has also worked across three continents, having been based in London, the US, where she led ViiV Finance for North America, and Singapore, where she led Supply Chain Finance for Asia Pacific, Latin America and Middle East and North Africa.
Commenting on the appointment, Said Darwazah, Hikma's CEO, said:
"I am delighted to welcome Becky to Hikma. She is an accomplished pharmaceutical leader who most recently led the finance department for a multi-billion-pound specialist pharmaceutical business, with experience extending into a broad range of organisational functions. She brings financial and operational discipline that will support the delivery of our strategic plans.
I would also like to thank Areb Kurdi for stepping into the Acting CFO role and for his support in delivering on our strategic priorities. Areb will continue as Acting CFO until Becky joins."
Victoria Hull, Chair of Hikma's Board of Directors, said:
"Becky's appointment is a further step in broadening the expertise we have across both the executive team and the Board, positioning us well for long-term sustainable growth."
Becky Hall, CFO Designate of Hikma, added:
"For more than 45 years, Hikma has built a strong track record of making high-quality medicines accessible to millions of people around the world. I am delighted to be joining the team and look forward to helping deliver Hikma's growth ambitions and creating lasting value for patients, shareholders and colleagues."
As Hikma Group CFO, Becky will join the Board as an Executive Director, replacing Khalid Nabilsi who will step down from the Board on 31 December 2026. Khalid will continue to serve on the Executive Committee in his role as Deputy CEO, North America and Europe.
About Becky Hall
Becky spent the first fourteen years of her career at GSK, progressing through commercial, strategic, corporate and supply chain finance roles across the UK, Europe and emerging markets. She also served as Chief of Staff to the GSK Group CFO in the CEO Office.
Becky joined ViiV Healthcare in 2018 as Global Finance Controller and Commercial Strategy Finance lead, before moving to the US as Vice President and Head of North America Finance. She was appointed Senior Vice President and Chief Financial Officer of ViiV in 2024. She holds a BSc in Economics from the University of Durham and qualified as a CIMA accountant in 2007.
Hikma confirms there is no further information required to be disclosed in relation to Rebecca Hall's appointment as a director pursuant to UK Listing Rule 6.4.8R.
Enquiries
Hikma (Investors):
|
Susan Ringdal EVP, Strategic Planning and Global Affairs |
+44 (0)20 7399 2760/ +44 (0)7776 477050 |
|
Guy Featherstone Sr Director, Global Investor Relations |
+44 (0)20 3892 4389/ +44 (0)7795 896738 |
FTI (Press):
Ciara Martin +44 (0)7779 775979
About Hikma:
Hikma helps put better health within reach every day for millions of people around the world. For more than 45 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across North America, the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 9,500 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com
Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB/stable S&P and BBB/stable Fitch)
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
ENDRNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.